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Cystic fibrosis (CF) is caused by a defect in the CF transmembrane regulator that leads to 
depletion and dehydration of the airway surface liquid (ASL) of the lung epithelium, providing 
an environment that can be infected by bacteria leading to increased morbidity and mortality. 
Pseudomonas aeruginosa chronically infects more than 80% of CF patients and one hallmark 
of infection is the emergence of a mucoid phenotype associated with a worsening prognosis 
and more rapid decline in lung function. Hypertonic saline (HS) is a clinically proven treatment 
that improves mucociliary clearance through partial rehydration of the ASL of the lung. Strikingly, 
while HS therapy does not alter the prevalence of P . aeruginosa in the CF lung it does decrease 
the frequency of episodes of acute, severe illness known as infective exacerbations among 
CF patients. In this article, we propose a hypothesis whereby the positive clinical effects of HS 
treatment are explained by the osmotic sensitivity of the mucoid sub-population of P . aeruginosa 
in the CF lung leading to selection against this group in favor of the osmotically resistant non-
mucoid variants.
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poorer lung function and increased risk of mortality than non-
infected peers (Govan and Deretic, 1996; Govan et al., 2007; Murray 
et al., 2007). The high incidence of specific P. aeruginosa infection 
in CF is probably not explained solely by a defect in mucociliary 
clearance, as P. aeruginosa infection is less frequently encountered 
and usually occurs later in life in patients with primary ciliary dys-
kinesia (Noone et al., 2004; Barbato et al., 2009). Without aggressive 
treatment of initial P. aeruginosa infection most CF patients will 
develop chronic lung infection (Gibson et al., 2003).
The Mucoid SwiTch
One hallmark of chronic P. aeruginosa CF infection is the emer-
gence of an alginate over-producing, mucoid phenotype, which is 
associated with worsening of prognosis and an accelerated loss of 
lung function (Lyczak et al., 2002; Ramsey and Wozniak, 2005). The 
algD operon (PA3540–PA3551) encodes the alginate biosynthetic 
genes and is under the regulatory control of the alternative sigma 
factor AlgU (AlgT) (Martin et al., 1993; Hershberger et al., 1995). 
The algU gene is in an operon with the mucABCD genes, which play 
a role in regulating AlgU activity. In particular, the MucA protein 
acts as an anti-sigma factor specific for AlgU. MucA, in combination 
with MucB sequesters AlgU at the membrane surface, preventing it 
forming a RNA polymerase holoenzyme complex and so directing 
transcription of its target genes (Schurr et al., 1996; Boucher et al., 
1997; Rowen and Deretic, 2000). The most common mechanism of 
mucoid switching by P. aeruginosa in the CF lung is through muta-
tion of the mucA gene (the mucA22 or muc-22 mutation being most 
inTroducTion
In this paper we will discuss the background to the use of hypertonic 
saline (HS) in the treatment of cystic fibrosis (CF) and propose a 
hypothesis whereby the positive effects of this approach can be 
explained by population shifts of Pseudomonas aeruginosa, the 
major chronic infecting bacterium of the CF lung.
cySTic FibroSiS and chronic Pseudomonas 
aeruginosa inFecTion
Cystic fibrosis is an inherited condition that results from mutations 
in the gene encoding the CF transmembrane regulator (CFTR), a 
cAMP-regulated chloride channel in epithelial tissues. These muta-
tions lead to disruption of normal ion and water transport across 
the epithelium and so to thickened, dehydrated airway secretions 
resulting in impaired mucociliary clearance (Collins, 1992; Ratjen 
and Doring, 2003; Campodonico et al., 2008). There is strong 
evidence to support an airway surface liquid (ASL) depletion/
dehydration theory and a model for ASL volume regulation and 
hence mucociliary clearance has been described for normal and 
CF epithelia (see Figure 1). This defect in the mucociliary escalator 
means that CF lungs are prone to chronic infection, which is the 
main cause of mortality and morbidity in CF patients (Dodge et al., 
2007). While experimental data supports the polymicrobial nature 
of CF airway infections there is little evidence for serious lung dam-
age occurring in CF in the absence of P. aeruginosa infection (Sibley 
et al., 2008; Tunney et al., 2008). P. aeruginosa chronically infects 
more than 80% of CF patients by adulthood leading to significantly 
Edited by:
Michael J. Schurr, University of 
Colorado, USA
Reviewed by:
Michael J. Schurr, University of 
Colorado, USA
Michael L. Vasil, University of Colorado, 
USA
Gerald Pier, Harvard Medical School, 
USA
*Correspondence:
Huw D. Williams, Department of Life 
Sciences, Imperial College London, 
South Kensington Campus, Sir 
Alexander Fleming Building, London 
SW7 2AZ, UK.  
e-mail: h.d.williams@imperial.ac.ukFrontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 120  |  2
Williams et al.  Hypertonic saline treatment of CF
TreaTMenT oF P. aeruginosa inFecTionS
The severity of P. aeruginosa infection can be limited by early detec-
tion and aggressive antibiotic treatment before the bacteria convert 
to a mucoid phenotype, but it is extremely difficult to eradicate 
once established (Doring et al., 2000; Ratjen, 2001, 2006; Davies, 
2006; Goss and Burns, 2007; Bendiak and Ratjen, 2009). When 
chronically infected, the patient will have repeated episodes of acute 
pulmonary exacerbations characterized by increased breathless-
ness, sputum production and feeling unwell and a reduction in 
lung function. Exacerbations are usually treated with a combination 
of systemic antibiotics (Davies, 2006; Bendiak and Ratjen, 2009; 
Foweraker, 2009); additionally, antibiotic therapy is supplemented 
by treatments designed to improve sputum clearance, such as chest 
physiotherapy and administration of nebulized recombinant deox-
yribonuclease (rhDNase), although the later approach is relatively 
expensive leading to restricted use in many countries (Jones and 
Wallis, 2003).
hyperTonic Saline TreaTMenT
An alternative or supplementary therapy to improve mucociliary 
clearance either in the context of a long term maintenance therapy 
or during infective exacerbations is the use of hypertonic saline 
hypertonic saline (HS). It is an inexpensive, straightforward treat-
ment during which nebulized HS (3–7% NaCl), is inhaled as a fine 
mist through a mask or a mouthpiece; typically, 10 ml of saline is 
inhaled twice a day (Wark and McDonald, 2009).
In vitro studies first indicated that HS might be a useful as a 
potential mucotropic approach as it was found to reduce the vis-
coelasticity and increase the predicted cough clearability of spu-
tum (King et al., 1997). A number of clinical studies followed that 
commonly encountered) that prevents the anti-sigma factor from 
sequestering AlgU, making it available to direct transcription of its 
target genes including the algD alginate biosynthetic operon. This 
mutation is a single base pair deletion that results in a truncated, 
dysfunctional MucA protein. AlgU-responsive promoter sequences 
are found for at least 35 genes and included many stress-induced 
genes (Firoved et al., 2002; Firoved and Deretic, 2003). The muta-
tion also affects the production of a number of virulence factors 
(Whitchurch et al., 1996; Carterson et al., 2004; Wu et al., 2004). 
The selective advantage of mutation-driven alginate production in 
the CF lung is unclear, but it has been proposed to protect against 
phagocytosis (Schwarzmann and Boring, 1971) and reactive oxygen 
species (Mathee et al., 1999). Mucoidy is not an essential require-
ment for biofilm formation in vitro, as alginate is not a major 
component of non-mucoid P. aeruginosa biofilms (Ramsey and 
Wozniak, 2005), but it is likely that mucoid P. aeruginosa are part 
of the persistent biofilm communities in the CF lung (Hassett et al., 
2009; Hoiby et al., 2010). Indeed, exposure to antibiotics triggers 
transient alginate production in vitro (Wood et al., 2006; Hoiby 
et al., 2010) and alginate-overproduction increases resistance to 
tobramycin in biofilm cultures (Hentzer et al., 2001). As more than 
80% of adult CF patients have mucoid P. aeruginosa, mucoid bio-
films may act as a reservoir for the infection of previously healthy 
parts of the lung through biofilm dispersal mechanisms that lead to 
the release of motile, non-mucoid bacteria (VanDevanter and Van 
Dalfsen, 2005; Kirov et al., 2007; Bjarnsholt et al., 2010), although 
this proposal has been challenged (Reid et al., 2006) and mucoid 
variants have been shown to be seeding dispersal proficient (Kirov 
et al., 2007). Treatments that would destroy or weaken biofilm struc-
tures may be of therapeutic benefit.
Figure 1 | The regulation of airway surface liquid (ASL) volume and 
Pseudomonas aeruginosa phenotype in normal, CF epithelia and CF 
epithelia following hypertonic saline treatment. (A) In normal epithelia 
CFTR (red sphere) plays a vital role in regulating the concentration of NaCl on 
airways surfaces, ensuring correct hydration of the ASL, which is comprised of 
the mucus and periciliary layers (PCL). (B) In the epithelia of the CF lung the 
PCL is depleted because of defective Cl− secretion due to CFTR mutation and 
through increased adsorption of Na+ ions through ENaC (green sphere), as a 
consequence of ENaC being locked in the Na+ adsorptive mode. This results in 
continued absorption of water from the airway surface and resulting depletion 
of ASL, collapse of the PCL and sticky, dehydrated mucus in contact with 
epithelial cells (Matsui et al., 1998; Boucher, 2007; Livraghi and Randell, 2007). 
The lack of PCL lubrication means that cilia cannot beat to move mucus out of 
the lung and this results in chronic bacterial infection indicated here by 
non-mucoid (open rectangle) and mucoid (filled rectangle) P . aeruginosa. (C) 
Following HS treatment it is proposed that ASL volume increases as it 
encourages transmembrane water movement and that this leads to a partial 
rehydration of the PCL and less sticky, partially rehydrated mucus and the 
possibility of some cilial beating-mediated mucus clearance. Furthermore, we 
propose that the increased salinity of the ASL leads to a shift in the P . 
aeruginosa population as consequence of the osmotic sensitivity of the mucoid 
P . aeruginosa and that this population shift impacts on the frequency of infective 
exacerbations. Note that in this cartoon we do not attempt to distinguish 
planktonic and biofilm bacteria.www.frontiersin.org  November 2010  | Volume 1  | Article 120  |  3
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spread of bacterial infection. They postulated the involvement of 
airway aquaporin water channels (AQPs) in the modulation of ASL 
volume. However, experimental evidence has subsequently been 
reported against this explanation of the data, indicating the need 
to identify alternate mechanisms (Levin et al., 2006).
An alternative is that HS treatment acts directly on the infecting 
bacteria in the CF lung, among which P. aeruginosa is usually the 
most prominent. P. aeruginosa motility was shown to be sensitive 
to NaCl exposure (Havasi et al., 2008) and the study suggests that 
the clinical benefits attributed to HS treatment might be in part 
due to these effects on bacterial motility. Although not specifically 
discussed in the paper, it is reasonable to think that a reduction 
in flagellin [which serves as a pathogen associated molecular pat-
tern (PAMP) and activates the innate immune response; Morris 
et al., 2009; Raoust et al., 2009; Campodonico et al., 2010] could 
lead to a reduction in inflammatory responses in the CF lung. The 
importance of motility during chronic infection of the CF lung 
remains uncertain, as P. aeruginosa is thought to populate the lung 
in biofilm-like communities (Moreau-Marquis et al., 2008; Davies 
and Bilton, 2009; Hassett et al., 2010) and following biofilm estab-
lishment the bacteria lose their flagella. However, motility might 
be involved in mobilization of P. aeruginosa to infect new sites in 
the lung using flagella-based swimming and swarming motility 
(VanDevanter and Van Dalfsen, 2005; Kirov et al., 2007).
an alTernaTive hypoTheSiS To explain The eFFecT oF 
hyperTonic Saline TreaTMenT on inFecTive 
exacerbaTionS
Based on recently published data we propose an alternative hypoth-
esis whereby long term HS treatment leads to a shift in P. aeruginosa 
sub-populations in the CF lung, away from mucoid variants, that 
are so strongly associated with increased morbidity, to non-mucoid 
strains.
We recently applied a nuclear magnetic resonance (NMR)-based 
extracellular metabolomics approach called time resolved metabolic 
footprinting (TReF; Behrends et al., 2009) to investigate metabolic 
changes in mucoid P. aeruginosa mucA22 mutants to determine the 
overall metabolic and physiological changes that are caused by the 
mucoid switch (Behrends et al., 2010). We found changes in the 
levels of various metabolites associated with osmotic tolerance, 
including glycine-betaine, trehalose, and glutamate in the mucoid 
mucA22 mutant. Quantitative comparison of the endometabolome 
of wildtype and isogenic mucA22 mutant cells showed differences 
in the accumulation of osmo-protectants, suggesting a switch in 
osmo-protectant preference from glycine-betaine to trehalose in 
the mucA22 mutant. Subsequent physiological experiments showed 
that the mucA22 mutant was significantly more sensitive to osmotic 
stress than the isogenic parental P. aeruginosa PA01 strain. The 
effect was tested over a concentration range of 0.2–0.8 M NaCl with 
mucoid P. aeruginosa showing increased sensitivity over the com-
plete range (Behrends et al., 2010). The mucA22 mutant was also 
more sensitive to the alternative osmotic stressor sucrose, showing 
it was not just an effect of NaCl.
Ambient NaCl concentrations in the CF lung are in the region 
of 0.15 M (Smith et al., 1996), so while the concentration that NaCl 
reaches in ASL or sputum following HS treatment is not known, it is 
likely that P. aeruginosa will encounter osmotic stress when NaCl at 
  supported the efficacy of nebulized HS in improving lung function 
in CF (Robinson et al., 1996, 1997, 1999). Two more recent clini-
cal studies have shown clearly the short and long term benefits of 
nebulized HS. Elkins et al. (2006) reported a double blind, placebo-
controlled, parallel group trial over 48 weeks of HS treatment in 
which 4 ml of HS (7%) was nebulized twice daily to CF patients 
with the control group receiving 0.9% saline. The rate of change 
in lung function was recorded as the forced vital capacity (FVC), 
forced expiratory volume in 1 s (FEV1) and forced expiratory flow 
at 25–75% of FVC (FEV25–75). While the individual measures did 
not show significant differences during the treatment period, a 
composite end point measurement (averaged FEV1 and FVC across 
all post-randomization visits) was found to be significantly different 
between the two groups.
More strikingly, the HS treated group had significantly fewer 
pulmonary exacerbations and a significantly higher percentage of 
patients without exacerbations. This is particularly important given 
that frequency of exacerbations is strong predictor of morbidity and 
mortality in CF and so a treatment that reduces exacerbations is of 
major clinical relevance. Interestingly, however, HS treatment did 
not significantly alter the concentrations or prevalence of either P. 
aeruginosa or common co-infector Staphylococcus aureus in sputum 
between treated and non-treated groups.
In a shorter but more intensive 2-week trial in which 5 ml of 
HS (7% NaCl) was administered four times daily a larger increase 
in pulmonary function was observed (Donaldson et al., 2006). No 
microbiological studies were done as part of this study.
A recent independent review of all controlled trials (12 in total) 
assessing HS compared to placebo or other mucolytic treatments 
concluded that HS does improve quality of life and reduces pul-
monary exacerbations and that there was sufficient evidence to 
recommend using HS on CF patients (Wark and McDonald, 2009). 
There are side effects of HS therapy that include more frequent 
coughing, sore throat and chest tightness in some patients, as HS 
can irritate the airways, and these can lead to patient compliance 
problems (Elkins et al., 2006). Inhaled mannitol is an alternative 
non-ionic osmotic agent to HS to promote airway rehydration and 
to increase mucociliary clearance. It has shown some promising 
effects on lung function, but its effects on pulmonary exacerbations 
and lung microbiology has not been tested (Robinson et al., 1999; 
Jaques et al., 2008; Minasian et al., 2008; Daviskas et al., 2010).
how doeS hyperTonic Saline TreaTMenT work?
The exact mechanism by which HS treatment works is unclear, 
but several ways as to how it could improve mucus clearance have 
been proposed: by inducing osmotic flow of water into the mucus 
layer so improving mucus rheology, through its action directly on 
the mucus, breaking the ionic bonds leading to lower viscosity and 
elasticity; and/or by increasing the ion concentration in the mucus 
and a subsequent reduction of intra and inter-molecular mucus 
repulsion leading to more compact mucus that could be more effec-
tively cleared (Robinson et al., 1997; Wark and McDonald, 2009).
Donaldson et al. (2006) proposed that HS produced a sustained 
increase in airway surface hydration and elevation in ASL volume 
that improves mucociliary clearance from the airways, so pro-
tecting relatively non-obstructed airways from exogenous insults 
that would slow mucus clearance and promote intrapulmonary Frontiers in Microbiology  |  Cellular and Infection Microbiology    November 2010  | Volume 1  | Article 120  |  4
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